Lanreotide
- Generic Name
- Lanreotide
- Brand Names
- Somatuline
- Drug Type
- Small Molecule
- Chemical Formula
- C54H69N11O10S2
- CAS Number
- 108736-35-2
- Unique Ingredient Identifier
- 0G3DE8943Y
- Background
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen Pharmaceuticals as...
- Indication
Lanreotide is indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy. It is also indicated in the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumo...
- Associated Conditions
- Acromegaly, Carcinoid Syndrome, Unresectable, locally advanced enteropancreatic neuroendocrine tumors, Unresectable, locally advanced well- or moderately-differentiated Gastroenteropancreatic Neuroendocrine Tumors, Unresectable, metastatic enteropancreatic neuroendocrine tumors, Unresectable, metastatic well- or moderately-differentiated Gastroenteropancreatic Neuroendocrine Tumors
- Associated Therapies
- -
Open-Label Extension of LOCKCYST Trial
- Conditions
- Interventions
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2008-11-13
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT00771888
- Locations
- 🇧🇪
University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium
🇳🇱Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Lanreotide as Treatment of Polycystic Livers
- Conditions
- Interventions
- First Posted Date
- 2007-11-29
- Last Posted Date
- 2009-02-17
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 38
- Registration Number
- NCT00565097
- Locations
- 🇧🇪
University Hospital Gasthuisberg, Leuven, Belgium
🇳🇱Radboud University Medical Center, Nijmegen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.